placebo + pegylated liposomal doxorubicin

Placebo + PLD is a control arm regimen used in clinical oncology trials, most notably the Phase 3 TRINOVA-2 study (NCT01281254) sponsored by Amgen. This combination consists of an inert placebo administered alongside pegylated liposomal doxorubicin (PLD), which is a liposomal formulation of the anthracycline chemotherapy doxorubicin (marketed as Doxil or Caelyx). The placebo serves as a comparator for an investigational agent (such as trebananib), while PLD provides the standard-of-care chemotherapy backbone. PLD functions by intercalating into DNA and inhibiting topoisomerase II, which disrupts DNA replication and leads to cell death. This regimen is primarily evaluated in patients with recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancers.

Brand names

DoxilCaelyx

Other names

placebo + PLDplacebo plus pegylated liposomal doxorubicinplacebo + Doxilplacebo + Caelyx